Pros:
- Richard met with tier 1 diagnostics groups in the US for the US roll-out
- News due in 'the coming weeks' around Mexico and Spain roll out
- Janseen collaboration going as planned, reiterating the potential use of PD every time Gliflozin is prescribed.
- FY19 receipts were $1.7M, more than double PY
- Upcoming $1.1m in R&D rebate to further strength cash position which is currently at $1.5M
Cons:
- Endometrosis POC delayed due to mass spectrometry machine failure
- Giardia POC now in a second POC stage? didnt' know 2 POC's were required..
- Dominican Republic royalties either not included or was minuscule
- Quarterly receipts only $245k
Overall pretty good just a dam shame we are taking so long to commercialize PromarkerD considering it was ready nearly 2 years ago.
One can dream but imagine what this means for us if we partner with a tier1 diagnostics group in the U.S and the Jannsen collaboration goes according to plan? Good luck guys and look forward to every one else thoughts on the quarterly.
- Forums
- ASX - By Stock
- PIQ
- Ann: Appendix 4C - June 2019 Quarterly Report
Ann: Appendix 4C - June 2019 Quarterly Report, page-2
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PIQ (ASX) to my watchlist
(20min delay)
|
|||||
Last
79.0¢ |
Change
0.020(2.60%) |
Mkt cap ! $103.4M |
Open | High | Low | Value | Volume |
77.0¢ | 79.0¢ | 77.0¢ | $98.88K | 126.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 15331 | 77.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
79.0¢ | 7886 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 10800 | 0.770 |
1 | 3000 | 0.760 |
2 | 7320 | 0.750 |
3 | 3830 | 0.740 |
1 | 14000 | 0.735 |
Price($) | Vol. | No. |
---|---|---|
0.790 | 7886 | 1 |
0.800 | 13740 | 2 |
0.820 | 8640 | 2 |
0.830 | 2986 | 2 |
0.840 | 10000 | 1 |
Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
Featured News
PIQ (ASX) Chart |